User:Mr. Ibrahem/Acalabrutinib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Acalabrutinib
Clinical data
Trade namesCalquence
Other namesACP-196
AHFS/Drugs.comMonograph
MedlinePlusa618004
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classBruton's tyrosine kinase inhibitor[2]
Legal status
Legal status
Identifiers
  • 4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide
Chemical and physical data
FormulaC26H23N7O2
Molar mass465.517 g·mol−1
3D model (JSmol)
  • CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
  • InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1
  • Key:WDENQIQQYWYTPO-IBGZPJMESA-N

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).[4][2] For CLL it may be used initially or in those who have failed other treatment.[2] It is taken by mouth.[3]

Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells.[4] Other side effects may include infection, bleeding, further cancer, and atrial fibrillation.[3] Use in pregnancy may harm the baby.[3] It is a Bruton's tyrosine kinase inhibitor, which slows the build-up of cancerous B cells.[2]

Acalabrutinib was approved for medical use in the United States in 2017 and Europe in 2020.[4][2] In the United Kingdom a month of medication costs the NHS about £5,100 as of 2021.[5] This amount in the United States is about 15,000 USD.[6]

References[edit]

  1. ^ a b "Acalabrutinib (Calquence) Use During Pregnancy". Drugs.com. 23 October 2019. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
  2. ^ a b c d e f g "Calquence EPAR". European Medicines Agency. 20 July 2020. Archived from the original on 17 November 2020. Retrieved 11 November 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ a b c d "Calquence- acalabrutinib capsule, gelatin coated". DailyMed. 22 November 2019. Archived from the original on 23 March 2021. Retrieved 11 November 2020.
  4. ^ a b c d e "Acalabrutinib Monograph for Professionals". Drugs.com. Archived from the original on 4 November 2019. Retrieved 16 March 2019.
  5. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1010. ISBN 978-0857114105.
  6. ^ "Calquence Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 18 January 2021. Retrieved 13 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Acalabrutinib&oldid=1215339795"